SÃ©bastien WÃ¤lchli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/415910/publications.pdf

Version: 2024-02-01

92 papers	2,860 citations	126907 33 h-index	189892 50 g-index
95 all docs	95 docs citations	95 times ranked	4193 citing authors

#	Article	IF	Citations
1	The Disulfide Isomerase Grp58 Is a Protective Factor against Prion Neurotoxicity. Journal of Neuroscience, 2005, 25, 2793-2802.	3.6	190
2	The ESCRT-III Subunit hVps24 Is Required for Degradation but Not Silencing of the Epidermal Growth Factor Receptor. Molecular Biology of the Cell, 2006, 17, 2513-2523.	2.1	159
3	Identification of Tyrosine Phosphatases That Dephosphorylate the Insulin Receptor. Journal of Biological Chemistry, 2000, 275, 9792-9796.	3.4	153
4	TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunology Research, 2019, 7, 355-362.	3.4	82
5	Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDTâ€“tamoxifen hybrid therapy. Npj Breast Cancer, 2019, 5, 13.	5.2	78
6	Shiga Toxin Regulates Its Entry in a Syk-dependent Manner. Molecular Biology of the Cell, 2006, 17, 1096-1109.	2.1	77
7	A TCR-based Chimeric Antigen Receptor. Scientific Reports, 2017, 7, 10713.	3.3	76
8	EDEM Is Involved in Retrotranslocation of Ricin from the Endoplasmic Reticulum to the Cytosol. Molecular Biology of the Cell, 2006, 17, 1664-1675.	2.1	73
9	Transport of Ricin from Endosomes to the Golgi Apparatus is Regulated by Rab6A and Rab6Aâ€². Traffic, 2006, 7, 663-672.	2.7	72
10	Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling. Blood, 2017, 129, 759-770.	1.4	69
11	Artesunate shows potent anti-tumor activity in B-cell lymphoma. Journal of Hematology and Oncology, 2018, 11, 23.	17.0	67
12	Axonal guidance protein FEZ1 associates with tubulin and kinesin motor protein to transport mitochondria in neurites of NGF-stimulated PC12 cells. Biochemical and Biophysical Research Communications, 2007, 361, 605-610.	2.1	64
13	Identification of Protein Tyrosine Phosphatases with Specificity for the Ligand-Activated Growth Hormone Receptor. Molecular Endocrinology, 2003, 17, 2228-2239.	3.7	63
14	PTPH1 Is a Predominant Protein-tyrosine Phosphatase Capable of Interacting with and Dephosphorylating the T Cell Receptor Î¶ Subunit. Journal of Biological Chemistry, 2004, 279, 7760-7769.	3.4	62
15	Glycosphingolipid Requirements for Endosomeâ€toâ€Golgi Transport of Shiga Toxin. Traffic, 2009, 10, 868-882.	2.7	60
16	Transiently redirected T cells for adoptive transfer. Cytotherapy, 2011, 13, 629-640.	0.7	58
17	Phosphoinositide-Regulated Retrograde Transport of Ricin: Crosstalk Between hVps34 and Sorting Nexins. Traffic, 2007, 8, 297-309.	2.7	57
18	T cell therapy targeting a public neoantigen in microsatellite instable colon cancer reducesin vivotumor growth. OncoImmunology, 2017, 6, e1302631.	4.6	57

#	Article	IF	Citations
19	NK cells specifically TCR-dressed to kill cancer cells. EBioMedicine, 2019, 40, 106-117.	6.1	56
20	Golgi Vesiculation Induced by Cholesterol Occurs by a Dynamin- and cPLA2-Dependent Mechanism. Traffic, 2005, 6, 144-156.	2.7	54
21	Phosphorylation of Fibroblast Growth Factor (FGF) Receptor 1 at Ser777 by p38 Mitogen-Activated Protein Kinase Regulates Translocation of Exogenous FGF1 to the Cytosol and Nucleus. Molecular and Cellular Biology, 2008, 28, 4129-4141.	2.3	53
22	The Mitogen-activated Protein Kinase p38 Links Shiga Toxin-dependent Signaling and Trafficking. Molecular Biology of the Cell, 2008, 19, 95-104.	2.1	52
23	Protein Kinase CÎ´ Is Activated by Shiga Toxin and Regulates Its Transport. Journal of Biological Chemistry, 2007, 282, 16317-16328.	3.4	51
24	Nuclear Import of Exogenous <scp>FGF</scp>1 Requires the <scp>ER</scp>â€Protein <scp>LRRC</scp>59 and the Importins <scp>Kpn</scp>Î±1 and <scp>Kpn</scp>Î²1. Traffic, 2012, 13, 650-664.	2.7	50
25	A Practical Approach to T-Cell Receptor Cloning and Expression. PLoS ONE, 2011, 6, e27930.	2.5	45
26	Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. Blood Advances, 2019, 3, 1230-1243.	5.2	43
27	Probing Protein-tyrosine Phosphatase Substrate Specificity Using a Phosphotyrosine-containing Phage Library. Journal of Biological Chemistry, 2004, 279, 311-318.	3.4	42
28	Splice variants of Enigma homolog, differentially expressed during heart development, promote or prevent hypertrophy. Cardiovascular Research, 2010, 86, 374-382.	3.8	42
29	Alloreactive cytotoxic T cells provide means to decipher the immunopeptidome and reveal a plethora of tumor-associated self-epitopes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 403-408.	7.1	40
30	Sap-1/PTPRH activity is regulated by reversible dimerization. Biochemical and Biophysical Research Communications, 2005, 331, 497-502.	2.1	39
31	Mapping of Synergistic Components of Weakly Interacting Protein-Protein Motifs Using Arrays of Paired Peptides. Journal of Biological Chemistry, 2003, 278, 15162-15167.	3.4	38
32	Treating osteosarcoma with CAR T cells. Scandinavian Journal of Immunology, 2019, 89, e12741.	2.7	36
33	SNX4 in Complex with Clathrin and Dynein: Implications for Endosome Movement. PLoS ONE, 2009, 4, e5935.	2.5	36
34	Î²-catenin is involved in N-cadherinâ€“dependent adhesion, but not in canonical Wnt signaling in E2A-PBX1â€“positive B acute lymphoblastic leukemia cells. Experimental Hematology, 2009, 37, 225-233.	0.4	35
35	Enigma homolog 1 scaffolds protein kinase D1 to regulate the activity of the cardiac L-type voltage-gated calcium channel. Cardiovascular Research, 2008, 78, 458-465.	3.8	34
36	A single point mutation in ricin A-chain increases toxin degradation and inhibits EDEM1-dependent ER retrotranslocation. Biochemical Journal, 2011, 436, 371-385.	3.7	32

#	Article	IF	Citations
37	Soluble T-Cell Receptors Produced in Human Cells for Targeted Delivery. PLoS ONE, 2015, 10, e0119559.	2.5	29
38	Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants. Molecular Therapy, 2016, 24, 1675-1685.	8.2	29
39	MetaBlasts: tracing protein tyrosine phosphatase gene family roots from Man to Drosophila melanogaster and Caenorhabditis elegans genomes. Gene, 2000, 253, 137-143.	2.2	23
40	BMP-7 induces apoptosis in human germinal center B cells and is influenced by TGF-Î² receptor type I ALK5. PLoS ONE, 2017, 12, e0177188.	2.5	23
41	Targeting B cell leukemia with highly specific allogeneic T cells with a public recognition motif. Leukemia, 2010, 24, 1901-1909.	7.2	22
42	Transcriptional targeting of small interfering RNAs into cancer cells. Biochemical and Biophysical Research Communications, 2006, 350, 854-859.	2.1	21
43	Characterization of clathrin and Syk interaction upon Shiga toxin binding. Cellular Signalling, 2009, 21, 1161-1168.	3.6	21
44	Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic Tâ€cell activation. European Journal of Immunology, 2014, 44, 774-784.	2.9	20
45	Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity. OncoImmunology, 2019, 8, 1558663.	4.6	20
46	Dendritic Cells Engineered to Express Defined Alloâ€HLA Peptide Complexes Induce Antigenâ€specific Cytotoxic T Cells Efficiently Killing Tumour Cells. Scandinavian Journal of Immunology, 2009, 69, 319-328.	2.7	19
47	PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. , 2022, 10, e002500.		19
48	Role of Smad Proteins in Resistance to BMP-Induced Growth Inhibition in B-Cell Lymphoma. PLoS ONE, 2012, 7, e46117.	2.5	18
49	Pulling Strings Below the Surface: Hormone Receptor Signaling Through Inhibition of Protein Tyrosine Phosphatases. Endocrine, 2001, 15, 019-028.	2.2	17
50	A Spheroid Killing Assay by CAR T Cells. Journal of Visualized Experiments, 2018, , .	0.3	17
51	T-helper cell receptors from long-term survivors after telomerase cancer vaccination for use in adoptive cell therapy. OncoImmunology, 2016, 5, e1249090.	4.6	16
52	Long-term surviving cancer patients as a source of therapeutic TCR. Cancer Immunology, Immunotherapy, 2020, 69, 859-865.	4.2	16
53	Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy. Molecular Therapy, 2021, 29, 1199-1213.	8.2	16
54	CARâ€Ts: new perspectives in cancer therapy. FEBS Letters, 2022, 596, 403-416.	2.8	16

#	Article	IF	Citations
55	Î²-arrestins attenuate p38-mediated endosome to Golgi transport. Cellular Microbiology, 2009, 11, 796-807.	2.1	15
56	Breadth and Dynamics of HLA-A2â€“ and HLA-B7â€“Restricted CD8+ T Cell Responses against Nonstructural Viral Proteins in Acute Human Tick-Borne Encephalitis Virus Infection. ImmunoHorizons, 2018, 2, 172-184.	1.8	15
57	Rab7b regulates dendritic cell migration by linking lysosomes to the actomyosin cytoskeleton. Journal of Cell Science, 2021, 134, .	2.0	14
58	Vector-based delivery of siRNAs: In vitro and in vivo challenges. Frontiers in Bioscience - Landmark, 2008, Volume, 3488.	3.0	13
59	Protein tyrosine phosphatases as drug targets: PTP1B and beyond. Expert Opinion on Therapeutic Targets, 2002, 6, 637-647.	3.4	12
60	Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy. Cancer Immunology, Immunotherapy, 2019, 68, 1235-1243.	4.2	11
61	Deciphering the Nongenomic, Mitochondrial Toxicity of Tamoxifens As Determined by Cell Metabolism and Redox Activity. ACS Chemical Biology, 2016, 11, 251-262.	3.4	10
62	Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors. OncoImmunology, 2021, 10, 1936757.	4.6	10
63	BiP Negatively Affects Ricin Transport. Toxins, 2013, 5, 969-982.	3.4	9
64	Pharmacologic Control of CAR T Cells. International Journal of Molecular Sciences, 2021, 22, 4320.	4.1	9
65	T cells raised against allogeneic HLAâ€A2/CD20 kill primary follicular lymphoma and acute lymphoblastic leukemia cells. International Journal of Cancer, 2012, 130, 1821-1832.	5.1	8
66	Human c-SRC kinase (CSK) overexpression makes T cells dummy. Cancer Immunology, Immunotherapy, 2018, 67, 525-536.	4.2	8
67	T cell receptor therapy against melanomaâ€”Immunotherapy for the future?. Scandinavian Journal of Immunology, 2020, 92, e12927.	2.7	8
68	Combinatorial CAR design improves target restriction. Journal of Biological Chemistry, 2021, 296, 100116.	3.4	7
69	Targeting B-cell neoplasia with T-cell receptors recognizing a CD20-derived peptide on patient-specific HLA. OncoImmunology, 2016, 5, e1138199.	4.6	6
70	Chimeric antigen receptor preparation from hybridoma to T-cell expression. Antibody Therapeutics, 2019, 2, 56-63.	1.9	5
71	SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy. Scandinavian Journal of Immunology, 2020, 92, e12917.	2.7	5
72	â€œBuiltâ€•PDâ€1 blocker to rescue NKâ€92 activity from PDâ€L1â€“mediated tumor escape mechanisms. FASEB Journal, 2021, 35, e21750.	0.5	5

#	Article	IF	Citations
73	Id2 Represses Aldosterone-Stimulated Cardiac T-Type Calcium Channels Expression. International Journal of Molecular Sciences, 2021, 22, 3561.	4.1	4
74	Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology. Methods in Molecular Biology, 2020, 2115, 445-454.	0.9	4
75	How CAR T Cells Breathe. Cells, 2022, 11, 1454.	4.1	4
76	Strategies for the Design of Random siRNA Libraries and the Selection of anti-GFP siRNAs. , 2005, 309, 083-092.		3
77	Reconstitution of active diphtheria toxin based on a hexahistidine tagged version of the B-fragment produced to high yields in bacteria. Toxicon, 2005, 46, 900-906.	1.6	3
78	Unpredicted phenotypes of two mutants of the TcR DMF5. Journal of Immunological Methods, 2015, 425, 37-44.	1.4	3
79	Colorectal cysts as a validating tool for CAR therapy. BMC Biotechnology, 2020, 20, 30.	3.3	3
80	In vivo experimental mouse model to test CD19CAR T cells generated with different methods. Methods in Cell Biology, 2022, 167, 149-161.	1.1	3
81	Sympathetic improvement of cancer vaccine efficacy. Human Vaccines and Immunotherapeutics, 2020, 16, 1888-1890.	3.3	2
82	Abstract 3773: Tapping CD4 T cells for cancer immunotherapy. , 2017, , .		1
83	Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?. Methods in Molecular Biology, 2020, 2115, 407-417.	0.9	1
84	Invariant chain as a tool to load antigenic peptides on MHC class I. Molecular Immunology, 2012, 51, 16.	2.2	0
85	Pulling Strings Below the Surface: Hormone Receptor Signaling Through Inhibition of Protein Tyrosine Phosphatases. Endocrine, 2001, 15, S19-S28.	2.2	0
86	Abstract 3146: T cell therapy targeting a neoantigen reducesin vivotumour growth. , 2015, , .		0
87	Abstract 2310: With a little help from CD4 T cells in adoptive T-cell transfer. , 2016, , .		0
88	Fishing therapeutic T-cell receptors in healthy donor blood, is safety predictable?. Translational Cancer Research, 2017, 6, S622-S624.	1.0	0
89	Abstract 3586: A universal killer T-cell for adoptive cell therapy of cancer. , 2018, , .		0
90	Abstract A035: Combinatorial IGK-CD19 CAR primarily targets IgK+ malignant B-cells and is less prone to serum IgG inhibition. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
91	Abstract 1422: Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma. , 2019, , .		0
92	Abstract 2318: Combinatorial IGK-CD19 CAR primarily targets IgK+ malignant B-cells and is less prone to serum IgG inhibition. , 2019, , .		0